Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Crosby

Plastic Surgery Sugar Land, TX Medical Doctor

NPI 1386744688 CMS profile 16919

16605 Southwest Fwy, Suite 300, Sugar Land, TX 77479

Open in the dashboard

General payments

$4,601

148 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Crosby of Sugar Land, TX is reported in the CMS Open Payments database as having received $4,601 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $366 16
2024 General $354 11
2023 General $561 20
2022 General $1,080 33
2021 General $884 31
2020 General $725 14
2019 General $631 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Crosby
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Melissa Crosby were reported at $366. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Melissa Crosby Plastic Surgery median Middle half National median
2019 $631 $371 $122–$1,483 $163
2020 $725 $158 $52–$438 $114
2021 $884 $249 $87–$752 $132
2022 $1,080 $274 $102–$793 $149
2023 $561 $299 $113–$891 $160
2024 $354 $361 $124–$1,062 $164
2025 $366 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $1,031 35 payments
  2. Galderma Laboratories, L.P. $711 12 payments
  3. Sientra, Inc. $650 12 payments
  4. AbbVie, Inc. $392 8 payments
  5. Integra LifeSciences Corporation $268 14 payments
  6. TELA Bio, Inc. $254 14 payments
  7. Tepha Inc $181 2 payments
  8. Bard Peripheral Vascular, Inc. $148 4 payments
  9. Allergan Inc. $147 8 payments
  10. Smith+Nephew, Inc. $96 6 payments
  11. Other $724 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,132 146 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $450 1 payment
  3. Travel and Lodging $19 1 payment
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $913 29 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $650 12 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS $381 7 payments
  4. SURGIMEND $215 12 payments
  5. GalaFLEX $181 2 payments
  6. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $158 7 payments
  7. NATRELLE $77 4 payments
  8. OviTex $73 5 payments
  9. CellerateRx $71 1 payment
  10. Santyl $50 4 payments
  11. Other $1,278 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

242

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,263

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

21.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 21 $848
Mupirocin Generic 63 $504
Ondansetron Odt Ondansetron Brand 36 $271
Levofloxacin Generic 39 $241
Acetaminophen-Codeine Acetaminophen With Codeine Brand 15 $104
Doxycycline Hyclate Generic 13 $101
Cephalexin Generic 14 $97
Gabapentin Generic 23 $64
Tramadol Hcl Generic 18 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$67,743

Medicare's payments for the services billed

Medicare patients

100

Average age 72

Services billed

304

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Cancer 69%
Arthritis 49%
Osteoporosis 32%
Ischemic heart disease 25%
Diabetes 20%
Chronic kidney disease 18%
Depression 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record